Cell and Gene Therapy Regulatory Landscape has evolved significantly over the past decade—from an emerging field requiring extensive regulatory caution to a maturing therapeutic modality supported by growing clinical, manufacturing, and regulatory experience.
As cell and gene therapy (CGT) continues to advance, the regulatory approach is also evolving. Regulators and developers now have access to a substantially larger body of evidence relating to genetically modified cells, vector platforms, manufacturing processes, potency, genome editing, long-term safety, clinical endpoints, and post-approval experience.
The challenge is therefore no longer simply determining how cell and gene therapies should be regulated, but how regulation can incorporate accumulated scientific knowledge while continuing to protect patient safety, product quality, and clinical efficacy.
This shift is particularly important as CGT development expands beyond oncology into rare diseases, hematology, ophthalmology, neurology, metabolic disorders, autoimmune diseases, and regenerative medicine.
What Is Cell and Gene Therapy Regulation?Cell and Gene Therapy Regulatory Landscape
Cell and gene therapy regulation refers to the regulatory frameworks, scientific requirements, clinical standards, manufacturing controls, safety assessments, and approval pathways used by regulatory authorities to evaluate cell-based and gene-based therapeutic products.
Cell and gene therapy products can involve fundamentally different biological mechanisms and manufacturing processes compared with conventional pharmaceutical products. Regulatory requirements may therefore address areas such as:
- Product characterization
- Manufacturing and CMC
- Potency assessment
- Vector safety
- Genome editing
- Biodistribution
- Persistence
- Immunogenicity
- Long-term follow-up
- Clinical trial design
- Comparability
- Post-approval safety and efficacy
- Regulatory submissions
In the United States, the FDA’s Office of Therapeutic Products maintains an approved-product framework covering a broad range of cellular and gene therapy products.
In Europe, the regulatory framework for Advanced Therapy Medicinal Products (ATMPs) encompasses gene therapy medicinal products, somatic cell therapy medicinal products, and tissue-engineered products.
CGT Is No Longer an Emerging Field
A decade ago, many cell and gene therapies were still being evaluated within relatively limited clinical and manufacturing experience. It was therefore appropriate for regulatory agencies and innovators to approach this emerging technology with considerable caution.
Long-term safety of genetically modified cells, durability of therapeutic effects, manufacturing consistency, potency, vector-related risks, immunogenicity, and potential delayed adverse events were not yet fully understood.
A cautious, product-specific regulatory approach was necessary to protect patients while the scientific and clinical knowledge base developed.
However, cell and gene therapy development has progressed considerably.
Regulatory agencies now have substantial experience evaluating CGT products, while patients have received approved therapies across multiple disease areas.
The FDA has stated that its Center for Biologics Evaluation and Research (CBER) has approved close to 50 CGTs over the past decade.
This accumulated experience has important implications for the future of the cell and gene therapy regulatory framework.
FDA Approved Gene Therapy and Cell Therapy Products Demonstrate Regulatory Maturity
The growing number of FDA-approved gene therapy and cell therapy products demonstrates how far the field has progressed.
Approved products span oncology, hematology, inherited diseases, ophthalmology, neurological disorders, and other therapeutic areas.
Examples include:
| Product | Brand Name | Class | Indication | Year |
| Tisagenlecleucel | Kymriah | CAR-T cell therapy | B-cell ALL; B-cell lymphomas; follicular lymphoma | 2017 |
| Axicabtagene ciloleucel | Yescarta | CAR-T cell therapy | B-cell lymphomas; follicular lymphoma | 2017 |
| Voretigene neparvovec | Luxturna | In-vivo AAV gene therapy | Biallelic RPE65 mutation-associated retinal dystrophy | 2017 |
| Onasemnogene abeparvovec | Zolgensma | AAV gene replacement therapy | Spinal muscular atrophy | 2019 |
| Brexucabtagene autoleucel | Tecartus | CAR-T cell therapy | Mantle cell lymphoma; B-cell ALL | 2020 |
| Lisocabtagene maraleucel | Breyanzi | CAR-T cell therapy | B-cell lymphomas; CLL/SLL; follicular lymphoma | 2021 |
| Idecabtagene vicleucel | Abecma | CAR-T cell therapy | Multiple myeloma | 2021 |
| Ciltacabtagene autoleucel | Carvykti | CAR-T cell therapy | Multiple myeloma | 2022 |
| Etranacogene dezaparvovec | Hemgenix | AAV gene therapy | Hemophilia B | 2022 |
| Betibeglogene autotemcel | Zynteglo | Gene-modified HSC therapy | β-thalassemia | 2022 |
| Elivaldogene autotemcel | Skysona | Gene-modified HSC therapy | Cerebral adrenoleukodystrophy | 2022 |
| Talimogene laherparepvec | Imlygic | Oncolytic viral gene therapy | Unresectable metastatic melanoma | 2015 |
| Nadofaragene firadenovec | Adstiladrin | Intravesical gene therapy | High-risk BCG-unresponsive non-muscle-invasive bladder cancer | 2022 |
| Delandistrogene moxeparvovec | Elevidys | AAV gene therapy | Duchenne muscular dystrophy | 2023 |
| Valoctocogene roxaparvovec | Roctavian | AAV gene therapy | Hemophilia A | 2023 |
| Lovotibeglogene autotemcel | Lyfgenia | Gene-modified HSC therapy | Sickle cell disease | 2023 |
| Exagamglogene autotemcel | Casgevy | CRISPR/Cas9 gene-edited cell therapy | Sickle cell disease; transfusion-dependent β-thalassemia | 2023/2024 |
| Atidarsagene autotemcel | Lenmeldy | Gene-modified HSC therapy | Metachromatic leukodystrophy | 2024 |
| Fidanacogene elaparvovec | Beqvez | AAV gene therapy | Hemophilia B | 2024 |
| Afamitresgene autoleucel | Tecelra | TCR-engineered T-cell therapy | Unresectable/metastatic synovial sarcoma | 2024 |
| Eladocagene exuparvovec | Kebilidi | AAV gene therapy | AADC deficiency | 2024 |
| Obecabtagene autoleucel | Aucatzyl | CAR-T cell therapy | Relapsed/refractory B-cell precursor ALL | 2024 |
| Remestemcel-L | Ryoncil | Mesenchymal stromal cell therapy | Steroid-refractory acute GVHD in pediatric patients | 2024 |
| Acellular tissue-engineered vessel | Symvess | Tissue-engineered vascular product | Extremity arterial injury requiring vascular conduit | 2024 |
| Prademagene zamikeracel | Zevaskyn | Autologous gene-corrected cell therapy | Wounds associated with recessive dystrophic epidermolysis bullosa | 2025 |
| Etuvetidigene autotemcel | Waskyra | Gene-modified autologous HSC therapy | Wiskott-Aldrich syndrome | 2025 |
| Marnetegragene autotemcel | Kresladi | Gene-modified autologous HSC therapy | Severe leukocyte adhesion deficiency-I | 2026 |
| Lunsotogene parvec | Otarmeni | AAV gene therapy | OTOF-related hereditary hearing loss | 2026 |
| Allogeneic regulatory T-cell immunotherapy | Tregzi | Allogeneic cellular therapy | Hematopoietic transplantation / chronic GVHD-free survival | 2026 |
The FDA’s current approved-product listing demonstrates the breadth of cellular and gene therapy products now in clinical use.
One particularly important milestone was Casgevy, which became the first FDA-approved therapy using CRISPR/Cas9 genome editing for sickle cell disease and transfusion-dependent beta-thalassemia.
The growing regulatory experience surrounding such products provides a foundation for increasingly informed CGT regulatory strategy.
Cell and Gene Therapy Is Moving Beyond Oncology
The evolution of CGT is particularly evident in the increasing number of applications outside oncology.
Cell and gene therapy development now extends into:
- Rare genetic diseases
- Hematological disorders
- Ophthalmology
- Neurological diseases
- Metabolic disorders
- Autoimmune diseases
- Regenerative medicine
- Tissue engineering
This expansion means that cell therapy regulatory requirements and gene therapy regulatory requirements increasingly need to account for different mechanisms of action, patient populations, biomarkers, clinical endpoints, manufacturing challenges, and long-term safety considerations.
The regulatory framework therefore cannot rely on a single development model for every CGT product.
What Is the Regulatory Framework for ATMPs in Europe?
In Europe, Advanced Therapy Medicinal Products (ATMPs) include gene therapy medicinal products, somatic cell therapy medicinal products, and tissue-engineered products.
The EU ATMP regulatory framework is established under Regulation (EC) No 1394/2007. EMA’s Committee for Advanced Therapies (CAT) plays a central scientific role in the assessment and classification of ATMPs.
The European framework also incorporates a risk-based approach and specific scientific and procedural guidance for advanced therapies.
For developers, this makes understanding European cell and gene therapy regulations, EMA requirements, ATMP classification, quality requirements, clinical development expectations, and marketing authorization procedures essential.
A global development strategy therefore needs to consider both:
- US cell and gene therapy regulations
- European cell and gene therapy regulations
rather than assuming that a single regulatory strategy can be applied identically across jurisdictions.
How Are Cell and Gene Therapies Regulated?
Cell and gene therapies are regulated through a combination of product-specific scientific assessment, manufacturing controls, nonclinical development, clinical trials, safety monitoring, and regulatory review.
Depending on the product, regulatory considerations can include:
Product Classification
Determining whether a product falls within a cell therapy, gene therapy, tissue-engineered product, combination product, or another regulatory category.
CMC and Manufacturing
Assessing the manufacturing process, starting materials, product characterization, potency, specifications, process controls, and manufacturing consistency.
Nonclinical Development
Evaluating pharmacology, toxicology, biodistribution, persistence, immunogenicity, and other product-specific safety considerations.
Clinical Development
Designing clinical trials that appropriately evaluate safety and efficacy while accounting for disease rarity, natural history, biomarkers, endpoints, and patient populations.
Long-Term Safety
Some CGTs require long-term follow-up because biological effects may persist for extended periods.
Regulatory Submission
Sponsors must compile appropriate scientific, manufacturing, clinical, and safety evidence for regulatory review.
The precise requirements depend on the nature and risk profile of the individual product.
The Regulatory Framework Is Also Evolving
Regulators have responded to the maturation of the field with an expanding body of cell and gene therapy regulatory guidance.
In the United States, FDA guidance currently addresses areas including:
- CMC requirements
- Long-term follow-up
- Potency assessment
- Manufacturing changes and comparability
- Genome editing
- CAR-T products
- Rare-disease gene therapy
- Retinal gene therapy
- Neurodegenerative disease
- Hemophilia
- Clinical trials in small populations
- Post-approval safety and efficacy data
- Individualized therapies
The FDA’s current cellular and gene therapy guidance portfolio includes guidance and draft guidance issued throughout 2026, including CMC flexibilities, genome-editing prior knowledge, genome-editing safety, individualized therapies, and CGT development FAQs.
FDA Guidance for Gene Therapy Is Becoming More Knowledge-Informed
The pace of regulatory development has accelerated significantly.
1. CMC Flexibilities for Developing Human Cellular and Gene Therapy Products
In May 2026, FDA issued final guidance describing its flexible approach to CMC requirements for human cellular and gene therapy products being developed for biologics license applications.
The guidance recognizes that CMC approaches can evolve during development and provides information on when flexibility may be appropriate.
2. Leveraging Prior Knowledge in Genome-Editing Gene Therapy
In June 2026, FDA issued draft guidance addressing how sponsors may leverage relevant public and platform knowledge in developing gene therapy products incorporating genome editing.
3. Genome-Editing Safety
FDA also issued draft guidance in 2026 addressing safety assessment of genome editing using next-generation sequencing.
4. Individualized Therapies
FDA’s 2026 guidance activity also includes a draft framework addressing individualized therapies targeting specific genetic conditions with known biological causes.
5. Small-Population Clinical Trials
The FDA has also developed guidance addressing innovative clinical-trial designs for CGT products where conventional trial designs may be challenging because of small patient populations.
6. Post-Approval Evidence
The FDA’s guidance portfolio includes approaches for capturing safety and efficacy data after approval, reflecting the importance of long-term evidence generation for CGT products.
These developments illustrate an important shift: FDA guidance for gene therapy is increasingly incorporating accumulated scientific and regulatory knowledge rather than treating every product as an entirely isolated scientific proposition.
Why Is a Risk-Based Approach Important for CGT Regulation?
A risk-based approach does not mean lowering regulatory standards.
Instead, it means aligning the level and type of evidence required with:
- The product’s mechanism of action
- Manufacturing platform
- Biological characteristics
- Patient population
- Route of administration
- Clinical risk
- Existing scientific knowledge
- Prior platform experience
- Available clinical evidence
For example, where established platform knowledge or prior manufacturing experience can scientifically support a development strategy, requiring sponsors to reproduce evidence that is already adequately established may not provide additional patient protection.
The objective should therefore be:
Regulate according to risk while maintaining rigorous standards for patient safety, product quality, and clinical efficacy.
This principle is increasingly relevant to global cell and gene therapy regulatory strategy.
Regulations Should Evolve With the Science
Regulatory agencies now have access to significantly more information about:
- Vector platforms and delivery technologies
- Cell-processing and manufacturing platforms
- Potency and analytical methodologies
- Genome-editing technologies
- Off-target assessment
- Immunogenicity
- Biodistribution and persistence
- Manufacturing changes and comparability
- Long-term safety
- Clinical endpoints and biomarkers
- Natural-history data in rare diseases
- Experience from previously approved CGTs
This accumulated knowledge should increasingly inform regulatory decision-making.
The objective should not be to reduce regulatory standards.
Instead, the objective should be to establish a science-based, risk-proportionate, and knowledge-informed regulatory framework in which sponsors can appropriately leverage established knowledge while continuing to demonstrate product-specific safety, quality, and efficacy.
FDA’s recent movement toward CMC flexibility and leveraging prior knowledge illustrates this evolving regulatory philosophy.
What Are the Challenges in Cell and Gene Therapy Regulatory Strategy?
Despite increasing regulatory experience, CGT development remains complex.
Key challenges include:
1. Complex Manufacturing
Cell and gene therapy CMC requirements can be highly product-specific because the manufacturing process may directly influence the biological characteristics of the final product.
2. Potency
Demonstrating an appropriate potency strategy can be challenging when the mechanism of action is complex or involves multiple biological pathways.
3. Long-Term Safety
Persistent biological activity, genomic modification, vector-related risks, or other mechanisms may require long-term safety monitoring.
4. Comparability
Manufacturing changes during development may require scientifically justified comparability assessments.
5. Small Patient Populations
Rare diseases can make conventional clinical trial designs difficult.
6. Genome Editing
Gene-edited therapies introduce additional considerations around off-target effects, genome integrity, editing efficiency, and long-term consequences.
7. International Development
Sponsors developing products across multiple markets must navigate differences between US, European, and other international regulatory frameworks.
For these reasons, international CGT regulatory strategy should be considered early rather than treated as an activity that begins immediately before regulatory submission.
The Next Phase of CGT Regulation
As CGT moves from an emerging technology toward an increasingly established therapeutic modality, regulatory frameworks should become more predictable, harmonized, adaptive, and scientifically informed.
The regulatory system should retain the necessary safeguards for:
- Patient safety
- Product quality
- Clinical efficacy
- Manufacturing consistency
- Long-term monitoring
while recognizing that the scientific knowledge base is no longer the same as it was when many early CGT regulatory frameworks were developed.
The future of cell and gene therapy regulation should therefore be built around three principles:
1. Learn From Accumulated Evidence
Regulators and sponsors should use scientifically relevant prior knowledge and platform experience where justified.
2. Regulate According to Risk
The depth and type of evidence should reflect the biological and clinical risks associated with the product.
3. Enable Innovation Without Compromising Patient Safety
Regulatory flexibility should support innovation without weakening the fundamental standards required for safe and effective therapies.
How Is Cell and Gene Therapy Regulation Evolving?
The evolution can be seen across several areas:
From product-by-product uncertainty → accumulated regulatory experience
From rigid development assumptions → scientifically justified flexibility
From isolated evidence generation → appropriate use of prior knowledge
From oncology-centric development → broader therapeutic applications
From traditional clinical-development models → innovative approaches for small populations and advanced therapies
This does not mean that CGT regulation is becoming less rigorous.
Rather, it is becoming increasingly informed by the evidence and experience accumulated from actual development programs and approved products.
CLINEXEL Perspective: Combining CGT Experience With Regulatory Expertise
At CLINEXEL, our engagement with advanced therapies has provided exposure to the scientific, clinical, operational, and regulatory complexities associated with cell-based therapies.
Our experience includes supporting programs involving mesenchymal stromal/stem cells (MSCs), including allogeneic cell-based approaches, where understanding the relationship between cell source, manufacturing process, characterization, potency, quality attributes, clinical application, and regulatory pathway is critical.
Our experience with MSC programs has reinforced an important principle:
CGT development cannot simply be approached by applying the conventional drug-development model to a cellular product.
The biological characteristics of the cells, manufacturing process, donor or starting material, characterization strategy, potency, immunogenicity, viability, mechanism of action, and long-term safety considerations all need to be evaluated within an integrated regulatory strategy.
CLINEXEL also brings regulatory knowledge spanning U.S. FDA, European, and other international regulatory frameworks, including:
- Clinical development requirements
- IND/CTA strategy
- CMC considerations
- GCP
- Safety reporting
- Clinical-trial authorization
- Regulatory authority interactions
- Regulatory submissions
This combination of CGT experience and regulatory expertise is particularly important as the field moves toward increasingly complex products, including:
- Allogeneic cell therapies
- Gene-edited cells
- Individualized therapies
- Combination approaches
- Regenerative medicine products
We believe the next phase of CGT development will require regulatory strategies that are not only compliant, but also science-driven, risk-based, and informed by accumulated knowledge.
The objective should be to leverage what is already known about established platforms, manufacturing technologies, analytical methods, and clinical experience wherever scientifically justified—while maintaining rigorous standards for patient safety, product quality, and clinical efficacy.
What Should Sponsors Consider When Developing a Global CGT Regulatory Strategy?
For sponsors developing cell and gene therapies, regulatory strategy should begin early and extend across the entire development lifecycle.
This may include:
- Product classification
- Regulatory pathway assessment
- CMC strategy
- Nonclinical development
- Clinical trial design
- Safety monitoring
- Long-term follow-up
- Manufacturing strategy
- Comparability planning
- Regulatory submissions
- Post-approval evidence generation
- International regulatory planning
A global cell and gene therapy regulatory strategy should also account for differences between jurisdictions and should consider how development activities can generate evidence that is useful across multiple regulatory pathways.
Frequently Asked Questions About Cell and Gene Therapy Regulation
What is cell and gene therapy regulation?
Cell and gene therapy regulation is the system of scientific, clinical, manufacturing, safety, and regulatory requirements used by authorities to evaluate cell-based and gene-based therapeutic products.
How are cell and gene therapies regulated?
Cell and gene therapies are regulated through product classification, CMC and manufacturing requirements, nonclinical studies, clinical trials, safety monitoring, regulatory submissions, and post-approval requirements. The specific pathway depends on the characteristics and risk profile of the product.
What are the regulatory requirements for cell and gene therapy?
Requirements can include product characterization, manufacturing controls, potency assessment, nonclinical safety, clinical development, long-term follow-up, comparability, regulatory submissions, and post-approval monitoring.
What is the FDA regulatory pathway for cell and gene therapy?
In the United States, CGT products are regulated through FDA’s biologics framework and may involve an IND during clinical development followed by a biologics license application for marketing authorization, depending on the product and applicable regulatory pathway.
How does the FDA regulate gene therapy products?
FDA evaluates gene therapy products across areas including manufacturing and CMC, nonclinical safety, clinical development, product quality, potency, long-term safety, and regulatory submissions. FDA’s current CGT guidance portfolio provides recommendations across multiple stages and product types.
What is the regulatory framework for ATMPs in Europe?
The EU ATMP regulatory framework covers gene therapy medicinal products, somatic cell therapy medicinal products, and tissue-engineered products. EMA’s Committee for Advanced Therapies provides scientific assessment and classification support within the European framework.
How does EMA regulate cell and gene therapies?
EMA regulates advanced therapies through the EU’s centralized framework for ATMPs, supported by scientific assessment, classification procedures, marketing authorization requirements, and post-authorization monitoring.
What are the CMC requirements for FDA Approved gene and cell therapy?
CMC requirements address aspects such as manufacturing processes, product characterization, quality controls, specifications, potency, process validation, and comparability. FDA’s 2026 CMC guidance recognizes that certain flexibilities may be appropriate during CGT development when scientifically justified.
What is the future of cell and gene therapy regulation?
The future of CGT regulation is likely to involve greater use of accumulated evidence, risk-based approaches, scientifically justified regulatory flexibility, improved international alignment, and development frameworks adapted to complex and individualized therapies.
Why is a risk-based approach important for CGT regulation?
A risk-based approach helps ensure that regulatory requirements are proportionate to the biological, manufacturing, and clinical risks of individual products while maintaining rigorous standards for safety, quality, and efficacy.
How is cell and gene therapy regulation evolving?
CGT regulation is evolving through increasing regulatory experience, product-specific guidance, greater use of prior knowledge, CMC flexibility, innovative clinical-development approaches, genome-editing guidance, and expanded regulatory frameworks for advanced therapies.
What are the challenges in cell and gene therapy regulatory strategy?
Key challenges include complex manufacturing, potency assessment, comparability, long-term safety, genome-editing considerations, small patient populations, evolving regulatory requirements, and differences between international regulatory frameworks.
Partner With CLINEXEL for Advanced Therapy Development
As cell and gene therapies continue to reshape the future of medicine, navigating the evolving regulatory landscape requires scientific expertise, strategic planning, clinical-development knowledge, and global regulatory insight.
Whether you are developing:
- Cell therapies
- Gene therapies
- Gene-edited therapies
- Regenerative medicine products
- Advanced therapy medicinal products
- Other innovative therapeutics
CLINEXEL can support your program across the development lifecycle—from regulatory strategy and clinical development to medical writing, clinical operations, pharmacovigilance, and regulatory submissions.
Our objective is to help sponsors translate complex regulatory requirements into scientifically sound, operationally feasible, and regulator-ready development strategies.
Partner with CLINEXEL to navigate advanced therapy development with confidence.
Website: https://clinexel.com/
Email: info@clinexel.com
Key Takeaway
The next phase of cell and gene therapy regulation is not about reducing regulatory rigor. It is about applying the knowledge gained from years of scientific, clinical, manufacturing, and regulatory experience to create development pathways that are risk-based, predictable, scientifically justified, and capable of supporting innovation without compromising patient safety.
Authors:
Dr. Deepa Arora- CEO- CLINEXEL (https://www.linkedin.com/in/deepaarora2019/)
Dr Deepa is a physician with 25+ years of industry experience in leadership positions with pharma in Clinical Development, Medical Research, and Drug Safety departments.
Dr. Deepa led an industry consortium for the implementation of additional risk minimization measures in Europe. Her experience includes the development and execution of clinical development strategy and conducting clinical trials for NCEs, biosimilars, vaccines, complex generics, and repurposed drugs.
Deepa has experience in interacting with various regulators- USFDA, EMA, MHRA, MEB, Health Canada, WHO, TGA for scientific advice, pre-IND meetings, end of phase meetings to discuss clinical development path, clinical trial designs, and post-marketing commitments, including PMS/ Phase IV studies and paediatric investigation plan (PIP).
Dr. Mukesh Kumar– Chief Scientific Officer- CLINEXEL (https://www.linkedin.com/in/dr-mukesh-kumar-m-d-6223457/)
A Physician (MD) with over 25 years of deep expertise in clinical R&D, Dr Kumar’s career is a testament to innovation and excellence in clinical trials, clinical pharmacology, translational research, biopharmaceutics, and clinical development. His contributions have driven global product registrations across regulatory landscapes, including the USFDA, EMA, India, PMDA, and ROW regions.
Dr. Kumar’s illustrious career includes clinical R&D leadership roles at global pharmaceutical giants (Sanofi and Daiichi Sankyo) and large Indian pharma companies (CIPLA, DRL, and LUPIN), where he supported early and late phase clinical trials of innovative products, including repurposed drugs via 505(b)(2) path, complex generics, and biosimilars. He has played a key role in transforming the R&D business through clinical risk mitigation strategies and high-quality clinical trial executions. With a proven track record of significant contributions in clinical development of over 100 successful product registrations in the U.S. and Europe, he has redefined efficiencies in clinical strategies by implementing cost-effective, innovative clinical trials and pharmacology studies.
As CLINEXEL’s CSO, Dr. Kumar oversees clinical trial operations (Phases I-IV) and clinical program management. His value-added support is available for CLINEXEL-managed clinical trials in optimizing clinical strategies, global clinical development, and driving impactful scientific negotiations for innovative therapies, biosimilars, and complex generics.